Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21WAF1/CIP1 dependent

International Journal of Cancer

Volumn 123, Issue 12, 2008, Pages 2931-2938

  Ding, Haiming ^a,d   Han, Chunhua ^a   Guo, Dongmei ^a   Wang, Dasheng ^b   Duan, Wenrui ^a   Chen, Ching Shih ^b,c   D'Ambrosio, Steven M ^a,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Division of Radiobiology   (United States)

Author keywords

Apoptosis; Cell cycle; Oral cancer; OSU03012; p21WAF1 CIP1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CELECOXIB; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; OSU 03012; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL LINE; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EMBRYO, MAMMALIAN; FIBROBLASTS; FLOW CYTOMETRY; G1 PHASE; GENE SILENCING; HUMANS; IMMUNOPRECIPITATION; MICE; MOUTH MUCOSA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS; PYRAZOLES; REPRESSOR PROTEINS; SULFONAMIDES; TUMOR VIRUS INFECTIONS;

EID: 57349154375     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23895     Document Type: Article

References (47)

1. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7:R796-R807.
2. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006;70:1534-41.
3. Caron RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, Dennis PA, Hagan MP, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 2005;4:257-70.
4. Tong Z, Wu X, Chen CS, Kehrer JP. Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer 2006;52:117-24.
5. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006;10:207-14.
6. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006;70:589-603.
7. Tseng PH, Lin HP, Zhu J, Chen KF, Hade EM, Young DC, Byrd JC, Grever M, Johnson K, Druker BJ, Chen CS. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005;105:4021-7.
8. Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther 2008;7:800-8.
9. Sargeant AM, Klein RD, Rengel RC, Clinton SK, Kulp SK, Kashida Y, Yamaguchi M, Wang X, Chen CS. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol 2007;35:549-61.
10. Zhu J, Huang J-W, Fowble JW, Tseng PH, Yang YT, Shiau C-W, Shaw Y-J, Kulp SK, Chen CS. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.
11. Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, Kulp SK, Kirschner LS, Saji M, Chen CS, Ringel MD. 2-amino-N-{4-[5-(2-phenanthrenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl]-phe nyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007;72:1124-31.
12. Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, Farag SS. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007;13:4750-8.
13. Park M, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan M, Calderwood S, Sherman M, Koumenis C, Spiegel S, Chen CS, Graf M, et al. OSU-03012 stimulates PERK-dependent increases in HSP70 expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008;73:1168-84.
14. Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel? Adv Exp Med Biol 2007;608:52-69.
15. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17:60-5.
16. Lee H, Li D, Prior T, Casto BC, Weghorst CM, Shuler CF, Milo GE. Ineffectiveness of the presence of h-ras/p53 combination mutations in squamous cell carcinoma cells to induce the conversion of a nontumorigenic to a tumorigenic tumor type. Cell Biol Toxicol 1997;13:419-34.
17. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000;29:413-25.
18. Erber R, Klein W, Andl T, Enders C, Born AI, Conradt C, Bartek J, Bosch FX. Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 1997;74:383-9.
19. Van Oijen MG, Tilanus MG, Medema RH, Slootweg PJ. Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med 1998;27:367-75.
20. Liu SC, Sauter ER, Clapper ML, Feldman RS, Levin L, Chen SY, Yen TJ, Ross E, Engstrom PF, Klein-Szanto AJ. Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. Cancer Epidemiol Biomarkers Prev 1998;7:597-603.
21. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
22. Russell M, Berardi P, Gong W, Riabowol K. Grow-ING Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 2006;312:951-61.
23. Darzynkiewicz Z. Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J Cell Biochem 1995;58:151-9.
24. Hochhauser D. Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drugs 1997;8:903-10.
25. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
26. Milo GE, Shuler C, Kurian P, French BT, Mannix DG, Noyes I, Hollering J, Sital N, Schuller DE, Trewyn RW. Nontumorigenic squamous cell carcinoma line converted to tumorigenicity with methyl methanesulfonate without activation of HRAS or MYC. Proc Natl Acad Sci USA 1990;87:1268-72.
27. D'Ambrosio SM, D'Ambrosio REG, Milo GE, Casto BC, Kelloff GJ, Steele VE. Differential growth responses of normal, premalignant, and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res 2000;20:2273-80.
28. Gibson-D'Ambrosio RE, Samuel M, D'Ambrosio SM. A method for isolating large numbers of viable disaggregated cells from various human tissues for cell culture establishment. In Vitro 1986;22:529-34.
29. Horner SM, DeFilippis RA, Manuelidis L, DiMaio D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 2004;78:4063-73.
30. Han C, Ding H, Casto BC, Stoner GD, D'Ambrosio SM. Inhibition of the growth of premalignant and malignant human oral cell lines by extracts and components of black raspberries. Nutr Cancer 2005;51:207-17.
31. Ding H, Han C, Gibson-D'Ambrosio R, Steele VE, D'Ambrosio SM. Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Int J Cancer 2003;107:830-6.
32. Ding H, Han C, Guo D, Wang D, Chen CS, D'Ambrosio SM. OSU03012 activates Erk1/2 and cdk2/cyclin A leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer 2008;(in press).
33. Ernster JA, Sciotto CG, O'brien MM, Finch JL, Robinson LJ, Willson T, Mathews M. Rising incidence of oropharyngeal cancer and the role of oncogenic human papillomavirus. Laryngoscope 2007;117:2115-28.
34. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol 2008;5:24-31.
35. Min BM, Baek JH, Shin KH, Gujuluva CN, Cherrick HM, Park NH. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Eur J Cancer B Oral Oncol 1994;30B:338-45.
36. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas MC, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002;23:1289-96.
37. Kawata S, Ariumi Y, Shimotohno K. p21(Waf1/Cip1/Sdi1) prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded tax. J Virol 2003;77:7291-9.
38. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004;10:1813-25.
39. Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006;17:402-12.
40. Lu Y, Yamagishi N, Yagi T, Takebe H. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 1998;16:705-12.
41. Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, Trask DK. Celecoxib toxicity is cell cycle phase specific. Cancer Res 2007;67:3801-8.
42. Sohn D, Essmann F, Schulze-Osthoff K, Janicke RU. p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res 2006;66:11254-62.
43. Golsteyn RM. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett 2005;217:129-38.
44. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003;13:65-70.
45. Drexler HC. The role of p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2003;2:438-41.
46. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-67.
47. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980-5.